Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492988 | 0.94 | LMNA (0.44) | PTGIRLMNAGAASMN1; SMN2CACNA1B | |
| SCHEMBL493314 | 0.93 | LMNA (0.39) | PTGIRLMNAGAASMN1; SMN2CACNA1B | |
| SCHEMBL493499 | 0.93 | CCR2 (0.40) | PTGIRLMNAGAASMN1; SMN2CACNA1B | |
| SCHEMBL493159 | 0.93 | BDKRB1 (0.38) | LMNAGAASMN1; SMN2CACNA1BBDKRB1 | |
| SCHEMBL493164 | 0.90 | LMNA (0.46) | LMNAGAASMN1; SMN2CACNA1BBDKRB1 | |
| SCHEMBL493538 | 0.88 | HTT (0.40) | PTGIRLMNASMN1; SMN2TRPA1 | |
| SCHEMBL493170 | 0.87 | LMNA (0.39) | LMNAGAASMN1; SMN2CACNA1BRORC | |
| SCHEMBL493982 | 0.87 | LMNA (0.37) | PTGIRLMNAGAASMN1; SMN2CACNA1B | |
| SCHEMBL492699 | 0.87 | PTGIR (0.38) | PTGIRLMNAGAASMN1; SMN2CACNA1B | |
| SCHEMBL492544 | 0.86 | PTGIR (0.41) | PTGIRLMNASMN1; SMN2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | PTGIR 121/4885LMNA 2485/4885GAA 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.